Among the 279 subjects, 238 (85%) completed the 6-week study.
Forty one subjects (15%) withdrew from the trial, 24 in the aripiprazole
group, and 17 in the risperidone group (nonsignificant difference
between two groups, p = 0.2269). Seventeen (6% of total) subjects
withdrew for lack of efficacy, nine (3%) withdrew their consents, two
(1%) withdrew for noncompliance, seven (3%) was lost to follow-up,
and five (2%) withdrew for other reasons (Table 2).